Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2020-01-12 Investor Presentation
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
ANP Presentation for SACHS 3rd Neuroscience Innovation Forum 24 pages 2.6MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about Antisense Therapeutics' clinical pipeline and Phase II study results for ATL1102 in Duchenne Muscular Dystrophy (DMD). It includes extensive clinical trial data, safety and efficacy results, scientific background, and study design. The content is focused on clinical trial progress and scientific data rather than a formal regulatory filing or financial report. The document is lengthy (15,000 characters) and contains substantive data and analysis, not just an announcement or summary. It is structured as a presentation for investors or stakeholders, highlighting the company's drug development progress and clinical trial outcomes. Therefore, the document best fits the category of an Investor Presentation (IP).
2020-01-12 English
ANP to Present at Neuroscience Innovation Forum in the US 2 pages 207.5KB
Regulatory Filings Classification · 90% confidence The document is an ASX announcement dated 10 January 2020 from Antisense Therapeutics Limited. It announces that the CEO will present at the Neuroscience Innovation Forum and provides background information on the company and its clinical trials. The document does not contain financial statements, detailed financial analysis, or regulatory filings. It is primarily an announcement of an upcoming investor presentation event and a summary of the company's clinical trial progress and business context. The document length is 6763 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is the presentation itself, only that it will be lodged later. Therefore, the document best fits the category of Investor Presentation (IP) announcement or related communication. However, since the presentation is to be lodged later and this document is the announcement of the presentation, it is not the presentation itself. Given the content and context, the best classification is Regulatory Filings (RNS) as a general announcement that does not fit other categories better, but since the document is an announcement of a presentation event and company update, and not the presentation itself, and not a report, RNS is appropriate.
2020-01-09 English
Appendix 3B and 708A notice 13 pages 541.4KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the number of securities issued, exercise prices, underwriting details, issue prices, and compliance with ASX rules. It includes calculations of placement capacity under ASX rules 7.1 and 7.1A, which relate to the company's ability to issue new shares without shareholder approval. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding a new issue of securities and application for quotation of additional securities. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital raising and share issuance. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length (15,000 characters) and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2020-01-02 English
Antisense Therapeutics Limited - Listed Options raise $5.5M 2 pages 157.7KB
Capital/Financing Update Classification · 100% confidence The document is an ASX announcement dated 3 January 2020 from Antisense Therapeutics Limited regarding the raising of $5.5 million through the exercise of listed options. It details the use of funds for advancing preparations for a Phase IIb clinical trial. The content focuses on a capital raising event, mentioning underwriting and option conversion, and includes background information about the company and its clinical trials. There are no financial statements, quarterly or annual results, nor is there any indication of a report being attached or published. The document is a direct announcement of a financing activity related to capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-01-02 English
Change of Director's Interest Notice (RM, MD, GM, GP, WG) 10 pages 346.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX Listing Rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including shares and options acquired or disposed, with specific dates and nature of changes. This type of document is a formal notification of personal share transactions by company directors and executives, commonly known as insider trades or director dealings. It is not a financial report, earnings release, or management discussion, but a regulatory disclosure of director share transactions. Therefore, the appropriate classification is 'Director's Dealing' (DIRS). The document length and detail confirm it is not a brief announcement or certification but a full notice of director dealings.
2019-12-23 English
Change in substantial holding 3 pages 207.2KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder, filed under the Corporations Act 2001 Section 671B. It details changes in voting power and shareholdings of a substantial holder, Platinum Investment Management Limited, in Antisense Therapeutics Limited. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document is not a financial report, earnings release, or management report, but a regulatory disclosure about shareholding changes.
2019-12-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.